GUILFORD, Conn.--(BUSINESS WIRE)--Swoop® portable MRI system receives CDSCO approval in India, expanding access to advanced brain imaging in a large, fast-growing healthcare market. ...

Core Insights - AtriCure, Inc. is a leading innovator in surgical treatments for atrial fibrillation (Afib) and related conditions, participating in the J.P. Morgan 44th Annual Healthcare Conference [1][2] Company Overview - AtriCure provides innovative technologies for the treatment of Afib, which affects over 59 million people globally [3] - The Isolator® Synergy™ Ablation System is the first FDA-approved device for treating persistent Afib [3] - AtriCure's AtriClip® Left Atrial Appendage Exclusion System is the most widely sold device for left atrial appendage management worldwide [3] - The Hybrid AF™ Therapy offers a minimally invasive solution for long-standing persistent Afib patients [3] - AtriCure's cryoICE cryoSPHERE® and cryoXT® probes are designed for temporary ablation of peripheral nerves to alleviate pain in various medical procedures [3]

Core Insights - Beyond Air, Inc. has expanded its international distribution network for LungFit PH to 39 countries, covering a population of over three billion people [1][2] - The company aims to leverage its unique nitric oxide delivery technology to gain significant market share in key international markets [2] - LungFit PH is designed to generate nitric oxide from ambient air, streamlining hospital operations and reducing environmental impact [3][6] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on using nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors [4] - The company has received FDA approval and CE Mark for LungFit PH, which is intended for treating neonates with hypoxic respiratory failure [4][8] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [4] Product Details - LungFit PH is a cylinder-free, phasic flow generator that can deliver nitric oxide at concentrations ranging from 1 ppm to 80 ppm [6] - The device is compatible with ventilators and aims to replace traditional high-pressure nitric oxide cylinders, offering operational benefits such as reduced inventory and improved safety [6][7] - Beyond Air plans to extend the use of LungFit technology for home treatment of chronic lung infections [7] Research and Development - The company has partnered with The Hebrew University of Jerusalem to develop treatments for autism spectrum disorder and other neurological conditions [5] - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring high concentrations of nitric oxide for targeting solid tumors in pre-clinical studies [5]

Core Insights - Axogen, Inc. is a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function [1] - The company will participate in the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, at 10:30 AM Pacific Standard Time [2] Company Overview - Axogen focuses on the science, development, and commercialization of technologies for peripheral nerve repair, aiming to make nerve repair the expected standard of care [3] - The company's product portfolio includes Avance® (acellular nerve allograft-arwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™ [4] - Axogen's products are available in multiple countries, including the United States, Canada, Germany, the United Kingdom, and Spain [4]

Core Insights - Philips has agreed to acquire SpectraWAVE, a Massachusetts-based medical device company focused on technologies for diagnosing and treating coronary artery disease, enhancing its position in the intravascular imaging and AI-driven healthcare sectors [1] - The acquisition will strengthen Philips' presence in the intravascular imaging, physiological assessment, and IVUS device market, which is projected to grow at a compound annual growth rate of 4% from 2024 to 2034 [1][2] Market Position - Philips currently holds an 88% market share in the global IVUS market, with North America being the largest market valued at $490 million [2] - The North American IVUS market is expected to grow by 6% during the 2024-2034 period, driven by increasing cardiovascular disease incidence and healthcare spending [2] Growth Drivers and Barriers - The growth in demand for IVUS medical devices is attributed to the rising incidence of cardiovascular diseases, an aging population, and high smoking rates in certain regions [2] - Barriers to adoption include the high cost of imaging techniques and a lack of specialized heart hospitals in some areas [2] Technological Advancements - Philips' acquisition includes the HyperVue Imaging System and X1-FFR technology, which enhance imaging capabilities and assist clinicians in stent placements [2] - The integration of SpectraWAVE's technologies with Philips' existing products is expected to increase IVUS procedure adoption rates and drive innovation in the cardiovascular and diagnostic imaging sectors [2]

Core Insights - Shanghai Kohope Medical Devices Co., Ltd. is investing $2.5 million in facility expansion to meet increasing demand for syringes and medical needles in the U.S. and Canada [1][2] - The expansion will result in a 20% increase in production capacity, enabling the company to serve customers in over 50 countries more effectively [2][6] - The new manufacturing lines will increase monthly output to 25 million units and improve delivery times to U.S. healthcare facilities [4][10] Strategic Expansion Details - The expansion includes the installation of advanced automated production equipment with real-time quality control systems [10] - The new lines will focus on high-demand products such as 1ml, 3ml, and 5ml syringes, as well as 21-gauge to 25-gauge medical needles [10] - The new distribution center in Newark, New Jersey, will reduce delivery times from 3-4 weeks to 3-5 business days and provide same-day emergency fulfillment capabilities [4][6] Market Response and Future Growth - The expansion follows a 35% year-over-year increase in North American orders during 2024, driven by demand from various healthcare facilities [16] - The company has secured contracts with three major U.S. healthcare group purchasing organizations (GPOs) effective early 2025 [17] - The global distribution network spans over 50 countries, ensuring consistent supply and fostering long-term relationships with healthcare institutions [17] Commitment to Innovation - The company is advancing research and development initiatives, including a new line of safety-engineered syringes with retractable needles scheduled for market introduction in late 2025 [19] - Shanghai Kohope Medical Devices emphasizes adapting product offerings and capabilities to meet evolving healthcare needs [20] Comprehensive Product Portfolio - The company offers a wide range of syringes and medical needles, accommodating diverse dosage requirements and medical practices [14] - Each product undergoes meticulous quality inspection to ensure compliance with regulatory requirements across different markets [15]

Core Insights - Senzime AB's Next-generation TetraGraph system has received regulatory clearance for sale in Japan, marking a significant milestone for the company in one of the largest healthcare markets globally [1][2][3] Company Overview - Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance patient outcomes and safety during surgery [5][6] - The TetraGraph system is recognized as best-in-class for monitoring neuromuscular transmission, utilized in thousands of operating rooms worldwide [5] Market Entry and Growth Strategy - Senzime entered the Japanese market in 2019 through a partnership with Fukuda Denshi, which has facilitated the adoption of TetraGraph technology in numerous hospitals [2][4] - The recent PMDA approval is expected to drive revenue growth through increased market penetration, system upgrades, and higher utilization rates of the TetraGraph system [2][3] Market Potential - The Japanese healthcare market features approximately 15,000 operating rooms and nearly 3 million major surgical procedures annually, indicating substantial revenue potential for Senzime's expanding product portfolio [4]

Core Insights - Nyxoah has announced the commercial launch of its Genio® system in the Netherlands, with successful implants performed at OLVG West and Zuyderland hospitals [1][2] - The Genio system is designed as a breakthrough therapy for Obstructive Sleep Apnea (OSA), providing an alternative for patients who cannot tolerate CPAP [2][3] - The launch reflects Nyxoah's ongoing expansion in Europe and the growing adoption of its bilateral, externally powered Genio therapy [2] Company Overview - Nyxoah is a medical technology company focused on innovative solutions for treating OSA, with its lead product being the Genio system, which is leadless and battery-free [3] - The company aims to improve the quality of life for OSA patients, who face increased mortality risk and cardiovascular issues [3] Product Features - The Genio system stimulates both branches of the nerve, is MRI-compatible, and can be upgraded via an external activation chip, making it a promising long-term solution [2] - The absence of an implanted battery and reliable performance in the supine position are highlighted as significant advantages of the Genio system [2] Regulatory Milestones - The Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [4] - Nyxoah has also completed IPOs on Euronext Brussels and NASDAQ, and received FDA approval for a subset of adult patients with moderate to severe OSA in August 2025 [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 5, 2026 [3]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary launch steps, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

New York, New York--(Newsfile Corp. - December 16, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ ...